Mesenchymal stem cell therapy on top of triple therapy with remdesivir, dexamethasone, and tocilizumab improves PaO(2)/FiO(2) in severe COVID-19 pneumonia

BACKGROUND: Despite patients with severe coronavirus disease (COVID-19) receiving standard triple therapy, including steroids, antiviral agents, and anticytokine therapy, health condition of certain patients continue to deteriorate. In Taiwan, the COVID-19 mortality has been high since the emergence...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chih-Hao, Chang, Kuan-Cheng, Lin, Yen-Nien, Ho, Mao-Wang, Cheng, Meng-Yu, Shih, Wen-Hsin, Chou, Chia-Huei, Lin, Po-Chang, Chi, Chih-Yu, Lu, Min-Chi, Tien, Ni, Wu, Mei-Yao, Chang, Shih-Sheng, Hsu, Wu-Huei, Shyu, Woei-Cheang, Cho, Der-Yang, Jeng, Long-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537613/
https://www.ncbi.nlm.nih.gov/pubmed/36213639
http://dx.doi.org/10.3389/fmed.2022.1001979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537613/
https://www.ncbi.nlm.nih.gov/pubmed/36213639
http://dx.doi.org/10.3389/fmed.2022.1001979

Ejemplares similares